Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 450

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease

Open access
Fermé, Christophe, Eghbali, Houchingue, Meerwaldt, Jacobus H., Rieux, Chantal, Bosq, Jacques, Berger, Françoise, Girinsky, Théodore, Brice, Pauline, van't Veer, Mars B., Walewski, Jan A., Lederlin, Pierre, Tirelli, Umberto, Carde, Patrice, Van Den Neste, Eric, Gyan, Emmanuel, Monconduit, Mathieu, Diviné, Marine, Raemaekers, John M.M., Salles, Gilles, Noordijk, Evert M., Creemers, Geert-Jan, Gabarre, Jean, Hagenbeek, Anton, Reman, Oumédaly, Blanc, Michel, Thomas, José, Vié, Brigitte, Kluin-Nelemans, Johanna C., Viseu, Fernando, Baars, Joke W., Poortmans, Philip, Lugtenburg, Pieternella J., Carrie, Christian, Jaubert, Jérôme, Henry-Amar, Michel·2007·New England Journal of Medicine

Abstract

BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year event-free survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P=0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. CONCLUSIONS: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus involved-field radiotherapy should be the standard treatment. (ClinicalTrials.gov number, NCT00379041 [ClinicalTrials.gov].).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa064601

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 450

Metadata

Authors
Fermé, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M. B., Walewski, J. A., Lederlin, P., Tirelli, U., Carde, P., Van Den Neste, E., Gyan, E., Monconduit, M., Diviné, M., Raemaekers, J. M. M., Salles, G., Noordijk, E. M., Creemers, G.-J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vié, B., Kluin-Nelemans, J. C., Viseu, F., Baars, J. W., Poortmans, P., Lugtenburg, P. J., Carrie, C., Jaubert, J., & Henry-Amar, M.
Venue
New England Journal of Medicine
Published
2007-11-08
Volume
357
Issue
19
Pages
1916-1927
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2125790189
Cited by
450
References
9
FWCI
19.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.